Bioventus Inc. (BVS) financial statements and ratios from SEC XBRL: revenue $568.09M (TTM), net margin 4.0%, revenue growth 3.8% YoY, P/E 18.6. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (TTM) | $568.09M |
| Net Margin | 4.0% |
| Revenue Growth (YoY) | 3.8% |
| EPS Growth (YoY) | 345.5% |
| FCF Growth (YoY) | -25.1% |
| P/E Ratio | 18.6 |
| EV / EBITDA | 11.8 |
| Price / Book | 3.65 |
| Price / Sales | 1.74 |
| FCF Yield | 9.3% |
| DCF Value (model) | $3.43 |
| DCF Upside vs Price | -76.0% |
| Altman Z-Score | 1.90 (grey) |
| Piotroski F-Score | 8/9 |
| Sector P/E (Healthcare) | 21.6 |
BVS overview · BVS earnings · BVS KPIs · BVS investor relations · BVS ownership · BVS peers · BVS filings
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.